YOLFTbeta
26

Korea Arlico Pharm Co.,Ltd.

260660 · KQ · Healthcare / Drug Manufacturers - Specialty & Generic

1,919.00KRW+14.00 (+0.73%)

Price History

Full chart

Market Stats

Previous Close1,905.00
Open1,904.00
Day Range1,845.00 – 1,940.00
52-Week Range2,150.00 – 5,663.57
Volume11.00K
Market Cap34.38B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield3.29%
Beta0.35
50-Day Avg2,420.90
200-Day Avg3,192.25

About

Korea Arlico Pharm Co.,Ltd. engages in the researches and develops, produces, and sells medicines in South Korea. The company provides ETC, OTC, medical device, and other products; and active ingredients. It offers products in the areas of circulatory system, anti-platelet, dementia, muscle relaxants, diabetes, NSAIDS and analgesics, ointment/cream, respiratory system, gastrointestinal, metabolic disease, antihistamines, anti-virus, genitourinary, alopecia, psychoneurotic, CNS, anthelmintics, and hypnotic diseases. Korea Arlico Pharm Co.,Ltd. was founded in 1992 and is headquartered in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Hang-Gu Lee
  • Headquarters7-21, Baumoe-ro 27-gil, Seoul, South Korea, Korea
  • Websitehttps://www.arlico.co.kr

Leadership

  • Mr. Hang-Gu LeeCEO & Representative Director · b. 1961
  • Dong Soo KimMD & Internal Accounting Manager

Financials

Income Statement

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Total Revenue167.74B187.15B190.44B201.20B
Growth (%)-+11.58%+1.75%+5.65%
Cost of Revenue60.81B76.98B90.64B96.90B
Gross Profit106.92B110.18B99.80B104.30B
Gross Margin63.74%58.87%52.40%51.84%
Operating Expense97.06B107.11B104.95B103.31B
Operating Income9.86B3.07B-5.16B989.24M
Operating Margin5.88%1.64%-2.71%0.49%
EBITDA12.47B9.83B2.55B6.00B
EBITDA Margin7.44%5.25%1.34%2.98%
Net Income8.03B3.06B-5.36B-605.35M
Net Income Margin4.79%1.64%-2.81%-0.30%
R&D6.53B4.18B4.54B5.47B
R&D as % of Total Revenue3.89%2.23%2.38%2.72%
Interest Expense968.39M1.59B2.10B2.16B
Interest Expense % of Total Revenue0.58%0.85%1.11%1.07%

Balance Sheet

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Total Assets153.54B173.48B172.36B171.84B
Total Liabilities64.99B84.40B92.68B93.64B
Total Equity88.55B89.08B79.68B78.20B
Cash23.40B19.07B15.48B19.31B
Net Debt7.41B27.01B34.58B29.40B

Cash Flow

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow4.84B7.15B-8.58B9.99B
Capital Expenditure21.74B23.52B3.68B5.96B
Free Cash Flow-16.90B-16.37B-12.26B4.03B
Dividends Paid1.05B1.95B1.95B1.13B
FCF to OCF-349.43%-229.05%142.88%40.35%
Dividend Paid to FCF-6.22%-11.92%-15.92%27.92%

Earnings

Report DateMar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate----------------------------------
EPS Actual-248.0993.7582.86113.79147.20200.55177.65143.55203.91205.79158.48-18.39142.99152.15-26.5559.41140.83155.31151.7520.60170.25311.78-17.66-260.50-124.84-187.4871.90-116.4726.5835.49-36.88-65.50-41.34-46.20
Surprise----------------------------------
Timing----------------------------------

Key Statistics & Ratios

Market Cap34.38B
Enterprise Value54.55B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.18
Price / Book0.45
Revenue (TTM)195.70B
Gross Profit (TTM)99.67B
EBITDA-3.01B
Profit Margin-1.46%
Operating Margin-9.76%
Return on Equity-3.67%
Return on Assets-2.91%
Shares Outstanding15.01M
Shares Float9.15M
Beta0.35
Dividend Yield3.29%
Dividend Rate75.00
Payout Ratio441.18%

Dividends

20251×
75.00Dec 29, 2025
20241×
75.00Dec 27, 2024
20231×
130.00Dec 27, 2023
20221×
130.00Dec 28, 2022
20211×
70.00Dec 29, 2021
20201×
63.49Dec 29, 2020
20191×
126.98Dec 27, 2019

Stock Splits

  • Jun 15, 20211.5:1
  • Dec 29, 20201.05:1